Targeting Metabolism: Innovative Therapies for MASLD Unveiled DOI Open Access
Weixin Wang, Xin Gao, Wei Niu

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4077 - 4077

Published: April 25, 2025

The recent introduction of the term metabolic-dysfunction-associated steatotic liver disease (MASLD) has highlighted critical role metabolism in disease’s pathophysiology. This innovative nomenclature signifies a shift from previous designation non-alcoholic fatty (NAFLD), emphasizing condition’s progressive nature. Simultaneously, MASLD become one most prevalent diseases worldwide, highlighting urgent need for research to elucidate its etiology and develop effective treatment strategies. review examines delineates revised definition MASLD, exploring epidemiology pathological changes occurring at various stages disease. Additionally, it identifies metabolically relevant targets within provides summary latest targeted drugs under development, including those clinical some preclinical stages. finishes with look ahead future therapy goal summarizing providing fresh ideas insights.

Language: Английский

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma DOI Creative Commons
Melchor Alpízar Salazar,

Samantha Estefanía Olguín Reyes,

Andrea Medina Estévez

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(1), P. 88 - 88

Published: Jan. 7, 2025

Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) stems from disrupted lipid metabolism in the liver, often linked to obesity, type 2 diabetes, and dyslipidemia. In Mexico, where obesity affects 36.9% of adults, MASLD prevalence has risen, especially with metabolic syndrome affecting 56.31% by 2018. can progress Steatohepatitis (MASH), 5.27% globally, leading severe complications like cirrhosis hepatocellular carcinoma. Background: Visceral fat distribution varies gender, impacting development due hormonal influences. Insulin resistance plays a central role pathogenesis, exacerbated high-fat diets specific fatty acids, hepatic steatosis. Lipotoxicity saturated acids further damages hepatocytes, triggering inflammation fibrosis progression MASH. Diagnosing traditionally involves invasive liver biopsy, but non-invasive methods ultrasound transient elastography are preferred their safety availability. These detect steatosis reasonable accuracy, offering alternatives biopsy despite varying sensitivity specificity. Conclusions: as disorder underscores its impact on public health, necessitating improved awareness early management strategies mitigate diseases.

Language: Английский

Citations

2
Metabolic dysfunction-associated steatotic liver disease in adults DOI
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella

et al.

Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 6, 2025

Language: Английский

Citations

2
Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States DOI Creative Commons
Fan Zhang, Longgen Liu, Wenjian Li

et al.

Nutrition Journal, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 14, 2025

The objective of this study was to investigate the association between sarcopenia and liver fibrosis in patients aged 18–59 years with metabolic dysfunction-associated steatotic disease (MASLD) assess potential as a risk factor for progression fibrosis. included 821 MASLD US cohort 3,405 Chinese cohort. Liver controlled attenuation parameters (CAP) stiffness measurements (LSM) were assessed by vibration-controlled transient elastography (VCTE) evaluate extent hepatic steatosis Sarcopenia measuring appendicular skeletal muscle mass (ASM) calculating ASMI. To analyze relationship sarcopenia, ASMI, fibrosis, logistic regression models, multivariate-adjusted restricted cubic spline (RCS) models employed, stratification interaction analyses. results demonstrated that exhibited markedly elevated significant advanced cirrhosis compared those without both cohorts. After adjusting confounding variables, identified an independent MASLD. A negative correlation observed ASMI severity progressive reduction associated increasing Additionally, non-linear feature evident some indicators. Subgroup analysis further corroborated finding harmful effect on consistent across all subgroups. may be Monitoring assist identifying individuals at patients.

Language: Английский

Citations

1
The Burden of Non-Malignant Metabolic Dysfunction-Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis from 1990 to 2021 DOI
Qichao Ge, Yuan Lin,

Mingwang Wang

et al.

Published: Jan. 1, 2025

Background: The burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing, yet there little regional understanding in the Western Pacific. This study aims mainly to report latest MASLD and trends Pacific region for period 1990-2021.

Language: Английский

Citations

0
Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease And Steatohepatitis: A Systematic Review and Network Meta-Analysis DOI
Jie Li, Wenjing Ni, Xue Bai

et al.

Published: Jan. 1, 2025

Background: Several randomized controlled trials (RCTs) have been conducted to evaluate treatment efficacy for metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH). This network meta-analysis compared the effectiveness of 11 promising targets under a frequentist framework (PROSPERO registration: CRD42024625681).

Language: Английский

Citations

0
Association Between Active DNA Demethylation and Liver Fibrosis in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD) DOI Open Access
Ilaria Barchetta, Michele Zampieri, Flavia Agata Cimini

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1271 - 1271

Published: Jan. 31, 2025

Metabolic-associated steatotic liver disease (MASLD) represents the most common chronic hepatopathy worldwide and an independent risk factor for cardiovascular mortality, particularly when fibrosis occurs. Epigenetic alterations, such as DNA methylation, may influence MASLD susceptibility progression; yet mechanisms underlying this process are limited. This study aimed to investigate whether active demethylation in peripheral blood mononuclear cells (PBMCs) from individuals with MASLD, alongside methylation mRNA levels of inflammation- fibrosis-related candidate genes, is associated fibrosis. For study, global intermediates (5-hydroxymethylcytosine [5hmC], 5-formylcytosine [5fC]) were quantified PBMCs 89 with/without using ELISA. Site-specific SOCS3, SREBF1, TXNIP was analyzed by mass spectrometry-based bisulfite sequencing; expression assessed via RT-PCR. Individuals moderate-to-high (estimated non-alcoholic steatohepatitis (NASH) index, FNI) progressively exhibited greater 5hmC 5fC levels. Higher FNI reduced SOCS3 gene increased TXNIP, IL-6, MCP-1 genes. In conclusion, elevated demethylation, well differential patterns which key regulators inflammation These epigenetic alterations mirror changes liver, potentially contribute fibrogenesis represent novel biomarkers progression toward

Language: Английский

Citations

0
The role of liver sinusoidal endothelial cells in metabolic dysfunction-associated steatotic liver diseases and liver cancer: mechanisms and potential therapies DOI
Hanjun Mo,

Pengfei Yue,

Qiaoqi Li

et al.

Angiogenesis, Journal Year: 2025, Volume and Issue: 28(2)

Published: Feb. 3, 2025

Language: Английский

Citations

0
The Impact of Incidental Hepatocellular Carcinoma in Liver Transplantation: A Growing Concern DOI
Alfredo Caturano, Enes Erul

Clinics and Research in Hepatology and Gastroenterology, Journal Year: 2025, Volume and Issue: 49(3), P. 102550 - 102550

Published: Feb. 6, 2025

Language: Английский

Citations

0
Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease DOI Creative Commons

Yunfei Wu,

Guojun Zheng, Fan Zhang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 10, 2025

Objective This study aimed to investigate the association between high-sensitivity C-reactive protein (hsCRP) levels and hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) assess its predictive efficacy. Methods The included 1,477 participants from United States 1,531 China diagnosed MASLD. Liver stiffness measurement (LSM) controlled attenuation parameter (CAP) were assessed by vibration-controlled transient elastography (VCTE) evaluate presence degree of steatosis. relationship hsCRP MASLD was examined using multivariable-adjusted restricted cubic spline (RCS) models. Additionally, subgroup analyses conducted potential heterogeneity among different characteristic subgroups. Results results demonstrated a significant correlation elevated an increased risk fibrosis, advanced cirrhosis US cohort (OR 2.22, 1.69, 2.85, respectively; all P <0.05). Chinese consistent those cohort, there positive 2.53, 3.85, 3.78, respectively, <0.001). RCS analysis revealed non-linear disparate inflection point values observed across cohorts (approximately 9 mg/L 4 cohort). impact on varied subgroups distinct characteristics. Conclusion present MASLD, notable dose-response relationships differences.

Language: Английский

Citations

0
Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study DOI Creative Commons
Joost Boeckmans, Linnea Widman, Ying Shang

et al.

European Journal of Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

It is unclear if the risk of hepatic decompensation or hepatocellular carcinoma (HCC) differs between patients with compensated alcohol-related liver disease (ALD)- and metabolic dysfunction-associated steatotic (MASLD)-cirrhosis. We investigated to develop HCC based on ALD MASLD as underlying etiology cirrhosis. All a new diagnosis in hospital-based outpatient care ALD- MASLD-cirrhosis Sweden 2002 2020 were identified using national registers. Hepatic was analyzed composite outcome HCC. Cox regression employed compare rates HCC, subsequent death. 1660 ALD-cirrhosis 943 identified. The median ages 64 years (IQR 57-70) 69 62-75) MASLD-cirrhosis, respectively. Patients consisted 69.4 % males, compared 47.6 males group. 581 (35 %) 284 (30 developed (median follow-up time: 25 months), resulting an adjusted hazard ratio 1.12 (ALD- vs. 95 %-confidence interval=0.88-1.41). mortality afterwards lower (adjusted 0.62, interval=0.39-0.97). comparable but after event tends be higher MASLD-cirrhosis.

Language: Английский

Citations

0